Helius Medical Regains Nasdaq Compliance Avoids Delisting

Helius Medical Technologies, a neurotech company specializing in therapeutic neuromodulation, has regained full compliance with Nasdaq's listing requirements, including equity and minimum bid price rules, as confirmed on July 7, 2025. The company will remain under a Mandatory Panel Monitor for one year, during which Nasdaq will closely observe its adherence to listing standards. Despite this compliance milestone, Helius faces significant financial and operational challenges, with bearish analyst ratings and a negative financial outlook, as reflected in its poor financial performance and technical indicators. Helius focuses on developing non-invasive platform technologies to amplify the brain’s ability to heal itself, with its flagship product, the Portable Neuromodulation Stimulator (PoNS®), aimed at improving quality of life for individuals with neurological disorders. Analyst consensus remains cautious, with an average price target implying a potential downside from current stock prices and a brokerage recommendation indicating a 'Hold' status. The recent fundraising to meet Nasdaq compliance is positive but does not substantially improve the company’s financial outlook.